Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharma Two B raises $30m for trial of Parkinson’s treatment
Pharma Two B, a privately held biopharmaceutical firm engaged in the development of treatments for Parkinson’s disease, has closed $30m financing round.
Drug Discovery
-
28 Feb 2017
-
28 Feb 2017
Advaxis licenses antigen delivery technology to Sellas for cancer immunotherapy development
Advaxis has licensed its Lm-based antigen delivery technology to Sellas, under a cancer immunotherapy collaboration that could generate up to $358m for Advaxis.
-
16 Feb 2017
Versant Ventures launches biotechnology firm Jecure Therapeutics
Versant Ventures has launched Jecure Therapeutics, a biotechnology firm focused on the discovery of novel therapeutics to treat non-alcoholic steatohepatitis (NASH) and liver fibrosis.
-
16 Feb 2017
X-Chem, Janssen extend inflammatory disease collaboration
X-Chem has expanded its collaboration with Janssen Biotech for the discovery of new drug leads for inflammatory disease treatment.
-
09 Feb 2017
Lilly’s Trulicity label updated to include use in combination with basal insulin for type 2 diabetes
Eli Lilly and Company has updated label of its once-weekly Trulicity (dulaglutide) to include use in combination with basal insulin for adults with Type 2 diabetes.
-
09 Feb 2017
Prexton Therapeutics raises €29m in Series B Financing
Prexton Therapeutics has closed a €29m Series B round led by Forbion Capital Partners and Seroba Life Sciences.
-
08 Feb 2017
US FTC sues Shire ViroPharma for delaying generic entry of Vancocin
The US Federal Trade Commission (FTC) has charged that Shire ViroPharma abused government processes via serial, sham petitioning to delay generics and maintain its monopoly over Vancocin HCl Capsules.
-
08 Feb 2017
Acticor Biotech raises €1.5m in new funding
Acticor Biotech, a bio-pharmaceutical company focused on the treatment of acute ischemic stroke, has raised €1,5m from CapDecisif Management.
-
07 Feb 2017
Chondrial Therapeutics secures $22.6m in Series A financing
Biotechnology company Chondrial Therapeutics, focused on the treatment of rare mitochondrial diseases, has secured up to $22.6m in Series A financing led by Deerfield Management besides naming a new president and CEO in Carole Ben-Maimon, MD.
-
03 Feb 2017
Soligenix’s SGX301 secures PIM status from UK MHRA to treat cutaneous T-cell lymphoma
Soligenix has secured Promising Innovative Medicine (PIM) designation from the UK Medicines and Healthcare Products Regulatory Agency for SGX301 (synthetic hypericin) to treat cutaneous T-cell lymphoma (CTCL).